GPR157

Across TCGA pan-cancer cohorts, GPR157 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GPR157 data layer compared with 22 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher GPR157 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GPR157 expression acts as an unfavorable survival marker.

BRCA, LIHC, and MESO are the cancer types where GPR157 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.162	0.924	<.001	12	view →
LIHC	OS	Median	All	0.226	0.773	.008	12	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GPR157–BRCA (OS)

Open the BRCA breakdown →